Martin Shkreli is scheduled to go head to head in court one week from now against the Federal Trade Commission, which has blamed him for utilizing anticompetitive strategies to drive up the cost of the AIDS treatment drug Daraprim.

Assuming that he loses his democratic offers in his medication organization Vyera as requested by the FTC, insiders say an intermediary fight for control of the company’s board will probably follow. The point of the extremists, sources told, is to wrest control away from Shkreli, who has been running Vyera from prison.

A significant shareholder and executive at Phoenixus, Vyera’s parent company, is expected to lead the charge, sources said. While the executive’s identity wasn’t immediately revealed, sources said the insider will team up with Jason Aryeh, who unsuccessfully tried to shake up the company’s board last year.

Their aim is to remove Shkreli and get the cost of Daraprim back to “pre-Shkreli levels,” as Aryeh put it this week in a interview.

“The plan is to eliminate Martin from the company, right the cost of Daraprim to pre-Shkreli levels, and make the wisest decision first with patients, physicians then shareholders,” Aryeh said.

Shkreli is as of now carrying out a seven-year sentence through 2023 for protections misrepresentation he submitted while running two hedge funds. The 38-year-old rose to reputation after he climbed the cost of life-saving AIDS treatment Daraprim from $17.50 to $750 a pill after obtaining the exclusive rights to it in 2015.

“Should be a very handsome investment for all of us,” Shkreli wrote in an email to a contact at the time.

The increment left a few patients confronting co-pays as high as $16,000 and started an objection that energized legislative hearings. The company was sued in government court in New York by the FTC and seven states: New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia.

On Tuesday, the FTC documented a request requesting the drug organization Vyera and its parent Phoenixus make Daraprim “available to any potential generic competitor at list price.” The FTC also ordered Vyera to pay up to $40 million to compensate victims.

Daraprim is utilized to treat toxoplasmosis, a contamination that can be destructive for individuals with HIV or other immune -system issues and can create significant issues for kids brought into the world to women tainted while pregnant.